Skip to main content
. Author manuscript; available in PMC: 2022 Sep 15.
Published in final edited form as: Cancer Res. 2022 Mar 15;82(6):1110–1127. doi: 10.1158/0008-5472.CAN-21-1397

Figure 2: SPECC1L-RET-rearranged sarcoma models are sensitive to RET inhibition.

Figure 2:

A. Sensitivity of HMSC, HMSC-RET and SR-Sarc-0001 cells to RET inhibitors was assessed using alamarBlue cell viability assay after 96 h treatment. Data represent the mean ± SD of 6 measurements. Resulting IC50 values and 95% confidence intervals are shown in the bottom right panel. B. Cells were treated with the indicated concentrations of selpercatinib for 90 min then whole-cell extracts were prepared for western blot profiling. C. Sensitivity of HMSC, HMSC-RET, and SR-Sarc-0001 cells to different RET, MEK, ERK, AKT, PI3K, or MTOR inhibitors was determined. IC50 values are shown as a bar plot. IC50 values and their 95% confidence intervals of HMSC-RET and SR-Sarc-0001 cells were compared to the parental HMSC cells to determine differential sensitivity. *P <0.05, ns – not significant.